Oral semaglutide overcame the challenge of delivering a peptide drug as a pill through an innovative absorption enhancer, achieving comparable blood sugar and weight benefits to the injectable form.
First oral GLP-1 RAOral semaglutide (Rybelsus) broke the barrier of oral peptide delivery, achieving HbA1c and weight reductions comparable to injectable semaglutide
What the researchers found
The clinical development of oral semaglutide progressed through key phases:
- Phase 1: Demonstrated dose-dependent HbA1c and body weight reductions; characterized pharmacokinetics and drug interactions with food, disease states, and concomitant medications; established optimal dosing conditions (fasting, minimal water, 30-minute wait before eating)
- Phase 2: Confirmed significant HbA1c and weight reductions comparable to subcutaneous semaglutide, guiding dose selection (3 mg, 7 mg, 14 mg)
- Phase 3 (PIONEER program): Demonstrated significant HbA1c reduction, weight loss, and cardiovascular safety
- The absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) was key to enabling gastric absorption and peptide stability
- Oral semaglutide (Rybelsus) became the first approved oral GLP-1 RA for T2DM
Why it matters
Making a peptide drug into a pill was considered nearly impossible for decades. Oral semaglutide's success opens the door for other oral peptide therapies — potentially transforming how patients take medications that currently require injections. Patient adherence improves dramatically when switching from injections to pills.
How the study worked
Comprehensive review of the clinical development program for oral semaglutide, covering Phase 1 (PK/PD, safety, dose-response), Phase 2 (dose-finding), and Phase 3 (PIONEER program) trials. Focuses on the pharmacological innovations that enabled oral peptide delivery.
What this study cannot tell us
Oral semaglutide has lower bioavailability than the injectable form, requiring specific dosing conditions (fasting, limited water, 30-minute wait) that may reduce convenience. The SNAC technology works primarily through gastric absorption, which may not be applicable to all peptide drugs. Higher doses are needed orally to achieve comparable effects to injection.
How to read the evidence
This review synthesizes data from multiple completed clinical trial phases (1, 2, and 3), including the pivotal PIONEER program that supported FDA approval. The underlying evidence is strong and well-established.
When this study was published
Published in 2025, this review provides a comprehensive retrospective of oral semaglutide's clinical development, useful for understanding both the drug and the oral peptide delivery technology.
The bigger picture
Oral semaglutide represents a pharmaceutical milestone — proving that peptide drugs can be effectively delivered orally. This technology platform (SNAC-based absorption enhancement) could be applied to other peptide drugs currently requiring injection, potentially revolutionizing how we deliver biologics and expanding patient access to peptide-based therapies.
Questions still open
- Can the SNAC technology be applied to make other injectable peptide drugs available as pills?
- Will next-generation oral peptide formulations eliminate the strict dosing conditions?
- How does long-term adherence with oral semaglutide compare to injectable forms in real-world use?
Common questions
Why is it so hard to make a peptide drug into a pill?
Is the oral semaglutide pill as effective as the injection?
Read the original research
Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.
Translational and clinical pharmacology, 33(1), 1-9
Citation
Won, Heejae; Cho, Joo-Youn; Lee, SeungHwan. (2025). Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.. Translational and clinical pharmacology, 33(1), 1-9. https://doi.org/10.12793/tcp.2025.33.e3